NeuroPace (NASDAQ:NPCE) Stock Moved Down to “Equal Weight” by Wells Fargo & Company

Wells Fargo & Company lowered shares of NeuroPace (NASDAQ:NPCE – Free Report) from an overweight rating to an equal weight rating in a report published on Friday morning, Marketbeat Ratings reports. Wells Fargo & Company currently has $9.00 target price on the stock.

NPCE has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th. JPMorgan Chase & Co. cut shares of NeuroPace from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $20.00 to $9.00 in a research report on Friday. Raymond James Financial set a $21.00 price objective on shares of NeuroPace in a research report on Tuesday, September 15th. Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Finally, Leerink Partners lowered shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 target price for the company. in a research report on Friday. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.50.

Check Out Our Latest Report on NPCE

NeuroPace Price Performance

Shares of NASDAQ NPCE traded down $4.46 during midday trading on Friday, hitting $7.56. 6,104,874 shares of the company’s stock were exchanged, compared to its average volume of 127,272. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The business’s fifty day moving average price is $13.21 and its two-hundred day moving average price is $14.75. The company has a market cap of $259.46 million, a price-to-earnings ratio of -13.50 and a beta of 1.98. NeuroPace has a 12-month low of $5.46 and a 12-month high of $19.60.

Hedge Funds Weigh In On NeuroPace

Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in shares of NeuroPace during the second quarter valued at about $41,000. Algert Global LLC grew its stake in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock worth $2,936,000 after purchasing an additional 5,218 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of NeuroPace in the second quarter worth about $157,000. Lazard Asset Management LLC increased its holdings in NeuroPace by 9.8% during the 1st quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock valued at $1,635,000 after purchasing an additional 11,078 shares during the period. Finally, Diversified Trust Co purchased a new position in NeuroPace during the 3rd quarter valued at about $153,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Key NeuroPace News

Here’s some of the latest news about NPCE:

  • Positive Sentiment: NeuroPace reported a Q3 loss of $0.03 per share, improved from a $0.11 loss a year earlier and better than analyst estimates. Zacks Q3 earnings report
  • Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
  • Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

See Also

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.